Literature DB >> 33427957

Liver injury during rivaroxaban treatment in a patient with AL amyloidosis.

Alan Marrinan1, L Shackleton2, C Kelly2, M Lavin2,3, S Glavey2,4, P Murphy2,4, J Quinn2,4.   

Abstract

Entities:  

Year:  2021        PMID： 33427957     DOI： 10.1007/s00228-020-03084-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  Hepatotoxicity of New Oral Anticoagulants (NOACs).

Authors:  Evangelia Liakoni; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

2.  Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.

Authors:  Paul B Watkins; Mehul Desai; Scott D Berkowitz; Gary Peters; Yves Horsmans; Dominique Larrey; Willis Maddrey
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

Review 3.  Mechanisms of drug-induced liver injury.

Authors:  Liyun Yuan; Neil Kaplowitz
Journal:  Clin Liver Dis       Date:  2013-08-01       Impact factor: 6.126

Review 4.  Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.

Authors:  Daniel Caldeira; Márcio Barra; Ana Teresa Santos; Daisy de Abreu; Fausto J Pinto; Joaquim J Ferreira; João Costa
Journal:  Heart       Date:  2014-01-29       Impact factor: 5.994

5.  Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.

Authors:  DaLi Feng; Imran S Syed; Matthew Martinez; Jae K Oh; Allan S Jaffe; Martha Grogan; William D Edwards; Morie A Gertz; Kyle W Klarich
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

6.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Authors:  Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

Review 7.  Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.

Authors:  Andrew B Song; Rachel P Rosovsky; Jean M Connors; Hanny Al-Samkari
Journal:  Vasc Health Risk Manag       Date:  2019-06-21

8.  Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature.

Authors:  Muhammad Baig; Kenneth J Wool; Jewell H Halanych; Rehan A Sarmad
Journal:  N Am J Med Sci       Date:  2015-09
  8 in total
  1 in total

1.  Acute Liver Failure after Treatment with Rivaroxaban for Aortic Thrombosis Associated with COVID-19 Infection and Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T).

Authors:  Ivana Jukic; Dorotea Bozic; Milos Lalovac; Mirela Pavicic Ivelja; Mislav Radic; Zeljko Sundov; Jonatan Vukovic
Journal:  Case Rep Gastroenterol       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.